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PERENCATAN KOLINA KINASE SEBAGAI SUATU PENDEKATAN 
ANTIAMOEBIK DALAM ENTAMOEBA HISTOLYTICA 
 
ABSTRAK 
Entamoeba histolytica (E. histolytica) ialah parasit punca amoebiasis yang 
menyebabkan penyakit kolitis ameba atau abses hati ameba. Pesakit dijangkiti 
amoebiasis dalam usus diberi rawatan dengan ubat metronidazole. Adalah dikhuatiri 
bahawa kekerapan pengunaan metronidazole dalam rawatan amoebiasis akan 
mewujudkan rintangan metronidazole dalam E. histolytica. Pendekataan baharu dalam 
rawatan menggunakan laluan CDP-kolina diterokai dalam kajian ini. Kajian 
perencatan dilakukan melalui kaedah perencatan enzim EhCK oleh perencat CK dan 
“knockdown” mRNA EhCK dengan kaedah “RNA interference”. Kolina kinase E. 
histolytica (EhCK) mengutamakan pengunaan kofaktor Mn2+ berbanding dengan Mg2+ 
yang selalunya diutamakan dalam CK spesis lain termasuklah manusia. Perbezaan 
dalam pengutamaan kofakor Mn2+ berkemungkinan wujudnya perencat EhCK yang 
tidak menjejaskan enzim CK manusia (hCK). Nilai Km dan Vmax enzim EhCK dan 
hCKα2 melibatkan kofaktor Mn2+ atau Mg2+ ditentukan melalui cara spektrofotometri 
asai gabungan piruvat kinase-laktat dehidrogenase (PK-LDH). Nilai IC50 EhCK dan 
hCKα2 ditentukan selepas kajian melibatkan beberapa perencat CK komersial (CK37, 
HC-3, HDTAB, flavopiridol, dan H-89). Hanya beberapa perencat dipilih untuk diuji 
ke atas trofozoit E. histolytica selama 48 jam bagi menentukan nilai EC50 setiap 
perencat. Kaedah perendaman siRNA dupleks digunakan untuk melenyapkan ekspresi 
gen EhCK. Jumlah ekspresi gen ditentukan melalui “real-time qPCR”. Kecekapan 
transfeksi siRNA ditentukan dengan pendarfluor siGLO RISC-Free Control siRNA. 
Nilai Km dan Vmax EhCK dengan kofaktor Mn2+ bagi kolina ialah 0.12 ± 0.030 mM 
xix 
 
and 34.12 ± 1.87 U/mg; bagi ATP pula, nilai Km dan Vmax ialah 1.61 ± 0.26 mM dan 
48.98 ± 2.14 U/mg. Aktiviti EhCK kurang cekap dengan kofaktor Mg2+. Nilai Km 
didapati lebih tinggi (0.20 ± 0.044 mM bagi kolina; 10.85 ± 2.33 mM bagi ATP) 
manakala nilai Vmax didapati menyusut (2.13 ± 0.14 U/mg bagi kolina; 3.02 ± 0.37 
U/mg bagi ATP). Nilai Km dan Vmax hCKα2 dengan kofaktor Mg2+ bagi kolina ialah 
0.12 ± 0.012 mM dan 71.4 ± 1.54 U/mg; manakala ATP pula ialah 0.67 ± 0.085 mM 
and 113.6 ± 5.13 U/mg. Berdasarkan nilai IC50 bagi kedua-dua enzim EhCK dan 
hCKα2, hanya tiga perencat enzim, CK37 (60.64 ± 14.67 µM vs IC50 untuk hCKα2 
68.41 ± 12.08 µM), flavopiridol (45.51 ± 15.50 µM vs IC50 untuk hCKα2 297.0 ± 
80.50 µM), dan H-89 (100.60 ± 17.41 µM vs IC50 untuk hCKα2 392.1 ± 36.62 µM) 
lebih efektif terhadap EhCK berbanding dengan hCKα2. Semua perencat yang diuji 
kurang berkesan dengan kofaktor Mn2+ berbanding dengan kofaktor Mg2+. Kajian ke 
atas trofozoit menunjukkan hanya perencat HDTAB, H-89 dan metronidazole yang 
masing-masing mempunyai nilai EC50 47.40 ± 7.22 µM, 32.44 ± 5.05 µM, dan 1.73 ± 
0.33 µM, berjaya mengakibatkan kematian trofozoit selepas 48 jam. Kecekapan 
transfeksi paling tinggi ialah 55% selepas merendam siGLO RISC-Free Control 
siRNA sebanyak 10 µg/mL selama 16 jam. Kepekatan 10 µg/mL digunakan dalam 
eksperimen transfeksi melibatkan siRNA kawalan positif GAPDH, siRNA EhCK, dan 
siRNA bukan sasaran GFP. Hasilnya ekspresi gen GAPDH menyusut sebanyak 99%, 
manakala ekspresi gen EhCK menyusut sebanyak 47% selepas transfeksi. Kajian ini 
telah mengenal pasti prencat EhCK dan siRNA yang berpotensi untuk diubahsuaikan 
bagi meningkatkan keberkesanan terhadap EhCK tanpa menjejaskan hCK. 
Penggunaan perencat dan siRNA yang khusus terhadap EhCK merupakan suatu 
pendekatan yang baru dalam menghalang tumbesaran E. histolytica melalui gangguan 
pada laluan biosintesis fosfolipid parasit tersebut.  
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INHIBITION OF CHOLINE KINASE AS AN ANTIAMOEBIC APPROACH 
IN ENTAMOEBA HISTOLYTICA 
 
ABSTRACT 
Entamoeba histolytica is the causative parasite for amoebiasis which manifests 
into amoebic colitis or amoebic liver abscess. Patients with intestinal amoebiasis are 
traditionally treated with metronidazole. There is concern for metronidazole resistance 
and the resistance pathway has been discovered in E. histolytica. A new antiamoebic 
approach via CDP-choline pathway is explored in this study. Inhibition studies were 
carried out by inhibition of EhCK enzyme by some potential CK inhibitors and via 
EhCK gene knockdown using RNA interference. E. histolytica choline kinase (EhCK) 
showed preference for Mn2+ as cofactor instead of Mg2+ that is usually used by choline 
kinases from other species including human. The unique preference for Mn2+ suggests 
the possibility of EhCK specific inhibitors not affecting the human host CK (hCK). 
Km and Vmax of purified EhCK and hCKα2 proteins were determined by pyruvate 
kinase-lactate dehydrogenase (PK-LDH) coupled assay with Mn2+or Mg2+ as cofactors. 
The IC50 values for EhCK and hCKα2 were determined with several commercial CK 
inhibitors (CK37, HC-3, HDTAB, flavopiridol, and H-89). Selected inhibitors were 
incubated with E. histolytica trophozoites for 48 hours to determine the EC50 for each 
inhibitor. Silencing of gene encoding EhCK was carried out using duplex siRNA via 
soaking method and the gene expression level was measured by real-time qPCR. 
Transfection efficiency was assessed with fluorescence siGLO RISC-Free Control 
siRNA. Values of Km and Vmax of EhCK with Mn2+ as cofactor for choline substrate 
were 0.12 ± 0.030 mM and 34.12 ± 1.87 U/mg, respectively.  For ATP substrate, the 
Km and Vmax were 1.61 ± 0.26 mM and 48.98 ± 2.14 U/mg, respectively. EhCK was 
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much less efficient with Mg2+ cofactor. The Km values were higher (0.20 ± 0.044 mM 
for choline; 10.85 ± 2.33 mM for ATP) and the Vmax decreased (2.13 ± 0.14 U/mg for 
choline; 3.02 ± 0.37 U/mg for ATP). Km and Vmax hCKα2 in Mg2+ for choline substrate 
were 0.12 ± 0.012 mM and 71.4 ± 1.54 U/mg, respectively and for ATP substrate the 
values for Km and Vmax were 0.67 ± 0.085 mM and 113.6 ± 5.13 U/mg, respectively. 
Based on IC50 values for EhCK and hCKα2, three inhibitors, namely CK37 (60.64 ± 
14.67 µM vs IC50 for hCKα2 68.41 ± 12.08 µM), flavopiridol (45.51 ± 15.50 µM vs 
IC50 for hCKα2 297.0 ± 80.50 µM), and H-89 (100.60 ± 17.41 µM vs IC50 for hCKα2 
392.1 ± 36.62 µM) were more potent against EhCK than hCKα2. All inhibitors tested 
also exhibited lower potency with Mn2+ as the cofactor compared to Mg2+. 
Trophozoites growth inhibition showed that only HDTAB, H-89 and control drug 
metronidazole with EC50 values of 47.40 ± 7.22 µM, 32.44 ± 5.05 µM, and 1.73 ± 0.33 
µM, respectively, could penetrate and induce cell death after 48-hour incubation. The 
highest transfection efficiency of 55% was obtained after soaking with 10 µg/mL of 
siGLO RISC-Free Control siRNA for 16 hours. siRNA concentration of 10 µg/mL was 
used for the transfection of positive control GAPDH, EhCK, and non-targeting GFP 
siRNAs. RNAi experiment concluded with positive control GAPDH downregulated 
by 99% while the level EhCK mRNA was downregulated by 47%. This study has 
identified potential EhCK inhibitors and siRNA for further modifications and testing 
to achieve higher potency against EhCK but not affecting hCK. The use of specific 
inhibitors and siRNA targeting EhCK could be novel approach to inhibit the growth 








Amoebiasis is an infectious disease caused by the parasitic Entamoeba histolytica. 
Centers for Disease Control and Prevention (CDC) reports that only 10% - 20% of E. 
histolytica infections are symptomatic, with asymptomatic cases possibly caused by 
the non-invasive E. dispar. Symptoms range from mild, such as loose feaces, stomach 
pain; to severe, such as amoebic dysentery (stomach pain, bloody stools, and fever) 
and amoebic liver abscess. Most infections happen via contaminated water and food 
sources due to inadequate sanitary facilities. It has been estimated that amoebiasis 
causes about 50,000 deaths globally (Jensen, 2015). The best way to eradicate this 
disease is to have good hygiene practices such as frequent hand washing and access to 
uncontaminated drinking water, apart from providing a clean and safe water source to 
the community. However, with at least 2 billion people globally drinking water from 
sources contaminated with faeces, amoebiasis and other water-borne diseases continue 
to be a threat to the bottom billions (WHO and UNICEF, 2017).  
 
Amoebiasis is routinely treated with nitroimidazole drugs, such as metronidazole and 
tinidazole. Cysts and trophozoites found in the intestine are treated with a combination 
of metronidazole and luminal agent. Due to the low cost and effectiveness of 
nitroimidazole drugs against anaerobic parasites, metronidazole has been the drug of 
choice for the past half a century. This raises a concern among physicians and scientists 
that metronidazole-resistance might develop if it is being used as a prophylaxis against 
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the non-invasive E. dispar, a morphologically similar species to E. histolytica that co-
exist in the human body (Löfmark et al., 2010).  
 
This study focuses on targeting one of the phospholipid synthesis pathway of E. 
histolytica – the CDP-choline pathway as a new anti-amoebic approach. Inhibition was 
performed at two levels. In vitro inhibition at the protein level uses selected 
compounds that target recombinant E. histolytica choline kinase (EhCK), whereas in 
vivo inhibition at the mRNA level uses synthetic short interfering RNA (siRNA) which 
specifically targets EhCK mRNA. Apart from investigating the prospect of CDP-
choline pathway as a new target for amoebiasis treatment, this study would also give 
an insight on the biochemistry and enzymatic properties of EhCK.  
 
1.2 Amoebiasis prevalence around the world 
Amoebiasis has higher prevalence in areas with poor sanitation facilities and its effects 
are more severe in children living in endemic areas (Anuar et al., 2012, Ximénez et al., 
2009). The true prevalence of E. histolytica has been overestimated due to 
morphological bias with the non-pathogenic E. dispar and E. moshkovskii (Haque et 
al., 2003). The prevalence data collected previously from asymptomatic individuals 
were mostly based on microscopic examination of cyst or trophozoites in stool that 
does not give a clear distinction between these species (Tshalaia, 1941, Clark and 
Diamond, 1991, Diamond and Clark, 1993). To clearly identify these species, 
molecular methods such as PCR, antigen-antibody detection with ELISA, and 




A study in Mexico which utilizes indirect hemagglutination assay (IHA) found that 
out of 60,000 serum samples, about 5,600 were positive, which translated to 8.4%  E. 
histolytica prevalence in Mexico (Caballero-Salcedo et al., 1994). The seroprevalence 
of E. histolytica infection varied by region in such that children living in an area with 
better water supply in South Africa was found to be infected by 2% of both E. dispar 
and E. histolytica but 50% of children living in areas with inferior sanitation was found 
to be infected by E. dispar alone (Jackson et al., 2000). The overall prevalence of E. 
histolytica infection in South Africa based on a 5-year study period using stool culture 
and isoenzyme analysis was 2.4%, with more amoebic liver abscess (ALA) cases 
reported (Stauffer et al., 2006). Feacal antigen ELISA detection employed in the rural 
area of Egypt found that prevalence of E. histolytica (21.4%) is slightly lower than E. 
dispar (24.2%) (Abd-Alla et al., 2000). Meanwhile in Cairo, amoebic colitis was 
present in 38% of acute diarrhoea patients with positive E. histolytica serology test 
(Abd‐Alla and Ravdin, 2002). 
 
In Malaysia, the prevalence study of amoebiasis was carried out among the aborigine 
communities using polymerase chain reaction (PCR) (Anuar et al., 2012). It was found 
that 3.2% of the Entamoeba-infected population investigated was due to E. histolytica 
whereas E. dispar and E. moshkovskii species were at 13.4% and 1.0%, respectively. 
A study in a Philippines mental institution, also using PCR detection method, had 
higher E. histolytica prevalence at 65.5% compared to 5.3% of E. dispar infected 
patients (Rivera et al., 2006). ALA incidence reported in Hue, Vietnam between 1990-
1998 was at an average of 21 cases in 100,000 individuals per year. Commercially 
available ELISA detection carried out among the ALA patients in an area in Hue City 
had unexpectedly low prevalence of 0.9% for E. histolytica (Blessmann et al., 2002). 
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While this finding is common in other endemic areas, it suggests that local factors such 
as gut flora or diet contribute to the infection. Similarly using ELISA, investigation in 
an urban slum area of Dhaka, Bangladesh showed that 80% of children participated in 
the study were infected by E. histolytica resulting to an incidence rate of 0.45 infection 
per child per year. However only a-fifth of the children had E. histolytica associated 
diarrhoea or dysentery. That study also showed that a repeat infection was seen in 53% 
of the children (Haque et al., 2006).  
 
Although infection is commonly associated with poor hygiene practices, contaminated 
water, and inadequate sanitization, there are other ways where E. histolytica is 
transmitted. A study in Australia conducted using PCR detection method showed that 
there were 3.4% of E. histolytica prevalence rate, 33.7% and 24.7% of E. dispar and 
E. moshkovskii respectively, although presence of the 3 Entamoeba species 
concurrently was more prevalent. Patients in Australia were associated with risk 
factors of travelling to endemic areas and homosexual men (Fotedar et al., 2007). 
Travelers to endemic areas are exposed via consumption of not properly cooked food, 
predominantly cold beverage, ice-cream and raw fruit on ice (De Lalla et al., 1992). In 
countries such as Japan, Taiwan, China, and South Korea, studies have shown that 
there has been an increased prevalence of E. histolytica among human 
immunodeficiency virus (HIV) patients other than intestinal parasites 
Cryptosporidium sp, Microsporidia sp, Isospora belli, and Cyclospora cayetenesis 
(Teklemariam et al., 2013). There is increasing prevalence of invasive amoebiasis 
among HIV patients and emerging concern that E. histolytica is spreading as sexually 
transmitted infections, among men who have sex with men, and female commercial 
sex workers (Yanagawa et al., 2016, Abdollahi et al., 2015, Hung et al., 2008, Ohnishi 
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et al., 2004). Physicians are advised to be aware of the complications and possibilities 
of invasive amoebiasis present in HIV patients. Measures should also be taken to 
prevent widespread of infection in non-endemic area. 
 
1.3 Biology of E. histolytica 
E. histolytica, one of the parasitic amoebas is a protozoon. Its life cycle is relatively 
simple and consists of two stages: the trophozoite stage and the cyst stage (Figure 1.1). 
The most common route of transmission is the feacal-oral route via cysts. Once cysts 
are ingested via E. histolytica contaminated water or food, the quadrinucleate cyst 
survives acidic stomach condition and travels to the alkaline terminal ileum to release 
eight feeding trophozoites in the large intestine. From here, there is a 90% probability 
that the infection is non-invasive. In non-invasive infection, after encystation occurs, 
trophozoites colonize the large intestine and reproduce by binary fission. Binary 
fission continues until encystation is triggered by gal/GalNAc lectin, mucin 
glycoproteins or other bacteria (Petri Jr et al., 2002). The cysts, and some trophozoites 
are then passed out from the body via feaces. Patients that have non-invasive infection 
might present symptoms such as diarrhoea and stomach discomfort. 
 
Patients that present symptoms such as bloody/watery diarrhoea, abdominal pain and 
tenderness, might be at risk of invasive amoebiasis. Only 10% of infection might 
develop into invasive amoebiasis. This happens when the colonized trophozoites start 
penetrating intestinal mucin layer and trophozoite lectin attaches directly to N-acetyl-
D-galactosamine, triggering a cascade of events that leads to host cell death. Once the  
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Figure 1.1  Life cycle of E. histolytica describing invasive and non-invasive 
infections (Villarreal, 2008).  
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intestinal epithelial surface ruptures, trophozoites move into the blood stream that 
allows them to travel to other organs such as liver, lungs, and (less likely) brain, 
causing abscesses (Hasudungan, 2013). Amoebic liver abscess (ALA) is the most 
common form of extraintestinal amoebiasis. Invasive amoebiasis is treated with 
nitroimidazoles, particularly metronidazole whereas non-invasive infection is treated 
with paromomycin (Haque et al., 2003). 
 
E. dispar which has morphological similarities with E. histolytica under microscopic 
examination might account for 90% of the non-invasive infections. By using antigenic 
and serological tests, it has been found that infection of the non-pathogenic E. dispar 
is 10 times more common than E. histolytica. Experts recommend that microscopically 
determined amoebiasis should not be treated unless E. histolytica is present in the 
patient. This is to reduce unnecessary drug use on E. dispar infections that does not 
cause any diseases and prevent drug resistance (Clark, 2000). 
 
E. histolytica trophozoites are extremely sensitive to physiochemical environment 
changes. Rounded trophozoites measure between 7 µM – 40 µM, with larger 
trophozoites (20 µM – 40 µM) found in amoebas obtained from liver or intestine and 
smaller ones (7 µM – 30 µM) found in non-dysenteric stools or in culture (Martínez-
Palomo, 1982). The plasma membrane of E. histolytica is about 10 nm thick (thicker 
than most mammalian cells) with the protoplasmic face (P face) of the plasma 
membrane in contact with ectoplasm consists of abundant and heterogeneous 
population of membrane particles such as integral proteins. The complementary 
extracellular face (E face) has lesser population of membrane particles (Figure 1.2). 


















Figure 1.2  Freeze-fracture image of E. histolytica P face (1) and E face (2). Like 
most of the eukaryotic cells, intramembranous particles are found more 
abundant on the P face (1) than the E face (2). Particle-rich depressions 
on P and E faces are indicated by arrowheads whereas particle-free 
small protrusions are indicated by arrows. Arrows on the bottowm left 






circular openings, a diameter of 0.2 µM – 0.4 µM which corresponds to the mouths of 
micropinocytic vesicles (Figure 1.3) (Martínez-Palomo, 1982).  
 
The membrane of E. histolytica trophozoite consists of several phospholipids (Figure 
1.4). The major phospholipid identified is phosphatidylcholine (PtdCho), followed by 
other species such as phosphatidic acid (PA), phosphatidylinositol (PI), 
phosphatidylserine (PS), ceramide aminoethyl phosphonate (CAEP), 
phosphatidylethanolamine (PtdEtn), sphingomyelin and other unidentified minor 
species (Aley et al., 1980). PtdCho is the major phospholipid species in whole cells 
and internal vesicles, followed by the second abundant CAEP and PtdEtn that are 
majorly located at the plasma membrane (Aley et al., 1980).  
 
1.4 Kennedy pathway – CDP-choline pathway  
The eukaryotic cell membrane is a phospholipid bilayer that is made up of different 
phospholipid species. Kennedy pathway consists of CDP-ethanolamine and CDP-
choline pathways. The CDP-choline and CDP-ethanolamine pathway is responsible 
for production of phosphatidylcholine (PtdCho) and phosphatidylethanolamine 
(PtdEtn), respectively (Figure 1.5). 
 
Both PtdCho and PtdEtn species are found ubiquitously in eukaryotes and several 
prokaryotes (Fagone and Jackowski, 2013). There are several ways of choline 
phospholipid metabolism. PtdCho formation via CDP-choline pathway starts from 
phosphorylation of cytosolic choline by choline kinase (CK). Phosphocholine (PC) is 
then converted to CDP-choline by choline phosphate cytidylyltransferase (CCT). 










Figure 1.3  Surface characteristics of E. histolytica. Seen in this image are minute 
openings that are known as micropinocytic vesicles (mv), lobopodia (L), 
and cytoplasmic protrusions (CP) (Gonzales-Robles and Martinez-






Figure 1.4  Graph represents composition of phospholipid in whole cells, 
internal vesicles and plasma membrane of E. histolytica. PC: 
PtdCho; CAEP: ceramide aminoethyl phosphonate; PE: PtdEtn; 
PS: phosphatidylserine; PI: phosphatidylinositol; Sph: 







Figure 1.5  E. histolytica Kennedy pathway illustrating 
phospatidylisopropanolamine, phosphatidylethanolamine, and 
phosphatidylcholine biosynthesis. Ispn: isopropanolamine; Ispn-P: 
phosphoisopropanolamine; CDP-Ispn: cytidine 
diphosphoisopropanolamine; PtdIspn: phosphatidylisopropanolamine; 
Etn: ethanolamine; Etn-P: phosphoethanolamine; CDP-Etn: cytidine 
diphosphoethanolamine; PtdEtn: phosphatidylethanolamine; CDP-
choline: cytidine diphosphocholine; PtdCho: phosphatidylcholine 




diacylglycerol cholinephosphotransferase (CPT) and PtdCho is formed. Another 
method involves de novo synthesis of choline, which is through the methylation of PE 
by phosphatidylethanolamine N-methyltransferase (PEMT), using 3 equivalents of S-
adenosylmethionine (SAM) (Smith, 1993). In mammals, the methylations occur 
mainly in the liver that produces 30% of hepatic PtdCho. Abolishment of PEMT 
activity does not cause any physiological changes in mice when coupled with dietary 
choline deficiency, however, it causes failure to synthesize PtdCho. This in turns 
decreases the PtdCho:PtdEtn ratio and increases the membrane permeability which 
leads to liver failure (Vance et al., 2007). 
 
CK and ethanolamine kinase (EK) are the first enzymes in the CDP-
choline/ethanolamine pathway to produce PtdCho and PtdEtn. In mammalians, CK 
exists in 3 different isoforms which are produced by 2 different genes. CHKA encodes 
CKα which has 2 different splice variants whereas CHKB encodes CKβ which is 60% 
homologous to CKα (Aoyama et al., 1998). These isoforms may present as 
homo/hetero dimers or tetramers in solution (Aoyama et al., 2004). The upregulation 
of CKα has been closely associated with tumorigenesis (Gallego-Ortega et al., 2009) 
whereas CKβ deficiency leads to muscle dystrophy and neonatal bone deformity in 
mice (Sher et al., 2006).  
 
The structure of CK from C. elegans was first elucidated by Peisach and team (2003). 
The structures of C. elegans CK (CKA-2) and hCKα2 have a typical eukaryotic protein 
kinase fold (Peisach et al., 2003). They differ at residues 262-281 (of hCKα2), a region 
with no catalytic relevance. Here, hCKα2 has an α-helix while CKA-2 has 2 short β-































Figure 1.6  Stereo diagram of hCKα2 monomer with the binding of ADP (ball-and-
stick in cyan) and phosphocholine (ball-and-stick in green). Blue: ATP 
binding loop; Cyan: dimer interface α-helix; Yellow: short β-strand 
links N and C-terminal domains; Red: Brenner’s motif; Green: choline 





functional regions such as Brenner’s motif (302-311), choline kinase motif (326-349), 
ATP-binding loop (107-114), dimer interface (175-190), and β-strand link (201-204) 
(Malito et al., 2006).  
 
Due to the involvement of CK and the role of its metabolite, PtdCho in phospholipid 
of most eukaryotic cells, it became an interesting anti-protozoan target in parasites 
such as Plasmodium falciparum, Entodinium caudatum, Leishmania infantum, and 
Theileria equi (Gopalakrishnan et al., 2016, Pulido et al., 2017, Bygrave and Dawson, 
1976). Notably in P. falciparum, the infection increases erythrocyte phospholipid 
content by 500%, mostly attributed to Plasmodium phospholipids (Sherman, 1979). 
Forty five percent of the increased phospholipids consisted of PtdCho (Vial and 
Ancelin, 1998). Since the discovery and identification of CK and EK in 1986, efforts 
to characterize and inhibit PfCK as an antimalarial target is currently underway 
(Ancelin and Vial, 1986, Choubey et al., 2006, Zimmerman et al., 2013, Serrán-
Aguilera et al., 2016).  
 
Using similar approach, this study focuses on E. histolytica CK (EhCK) as a target to 
inhibit trophozoite proliferation. The sequencing of E. histolytica genome revealed 
metabolic pathways present in the species. The presence of these pathways allow 
development of new chemotherapeutic drugs and targets for anti-amoebic agents 
(Loftus et al., 2005). EhCK and EhEK have been characterized in the previous study 
by Chang (2012). Unlike other CKs that may phosphorylate substrate ethanolamine 
(Gibellini and Smith, 2010), EhCK was proven to be choline specific and was active 
between 37°C - 42°C. It has a narrow pH activity between pH 7.0- pH 8.5, with 
optimum activity at pH 8.0 (Chang, 2012). The preference of alkaline condition of 
EhCK is consistent with other CKs (Gee and Kent, 2003). Metabolomic analysis based 
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on the reassembly and reannotation of E. histolytica genome in 2010 reveals that the 
Kennedy pathway of E. histolytica includes CDP-choline, CDP-ethanolamine, and 
CDP-isopropanolamine pathways (Figure 1.5). E. histolytica trophozoite has PtdCho 
as its major phospholipid species with CAEP and PtdEtn most abundant in the cell 
membrane (Aley et al., 1980).  
 
1.5 Selection of inhibitors targeting choline kinase 
Choline kinase is an important target in rheumatoid arthritis, malaria, and cancer. CK 
inhibitors prevent cartilage destruction in rheumatoid arthritis by suppressing 
aggressive behavior of fibroblast-like synoviocytes from migration and reduce its 
resistance to apoptosis (Guma et al., 2015). In antimalaria studies, CK inhibitors were 
found to induce parasite death by blocking intraerythrocytic development of 
Plasmodium falciparum (Zimmerman et al., 2013). PfCK has sequence and structure 
similarities to hCKα which allows human CK inhibitors to inhibit PfCK in low 
nanomolar concentrations (Zimmerman et al., 2013). In cancer, hCKα was found to be 
upregulated by different growth factors and oncogene-coding proteins in cancer cells. 
It participates in tumorigenesis due to its role in biosynthesis of PtdCho (Huang and 
Freter, 2015). Apart from its involvement in tumor cells, hCKα became an anticancer 
target because inhibition of CK does not alter PtdCho biosynthesis of non-
tumorigeneic cells (Lacal, 2015). 
 
The first CK inhibitor found was hemicholinium-3 (HC-3) used in the nervous system. 
HC-3 blocked choline uptake into presynaptic terminals, preventing the formation of 
acetylcholine (Gomez et al., 1970). Subsequently in the brain, it was shown to block 
sodium-dependent high affinity choline uptake, reducing acetylcholine synthesis 
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(Gardiner, 1961). The off-target effects when HC-3 was used for in vivo studies 
prompted scientist to explore derivatives to improve its specificity on the neuronal 
choline transporters and acetylcholinesterase (Cannon, 1994). Lacal’s group 
developed a new CK inhibitor based on structures of prior HC-3 derivatives. The 
synthesized bis-pyridinium compounds gave good potency against purified CK and 
cancer cells (Campos et al., 2001). One of the compounds developed – MN58b had 
higher specificity than HC-3 and exhibited growth retardation in several cancer cell 
lines (Hernández-Alcoceba et al., 1997). Since then, scientists have been working on 
several aspects of CK inhibitors to improve their antiproliferative properties, potency, 
and specificity. Changes have been made from using different class of compounds, 
down to improvisation on the length and structure of linker, distance between 
quaternary ammoniums, steric hindrance, and delocalization of positive charge 
(Janardhan et al., 2006, Arlauckas et al., 2016). This study utilizes CK inhibitors to 
investigate its potential anti-amoebic properties by disrupting E. histolytica’s PtdCho 
biosynthesis.  
 
The synthetic 5-nitroimidazole, metronidazole has been used in treatment of anaerobic 
bacteria and is the recommended drug in treating amoebiasis for the past 50 years 
(Löfmark et al., 2010). Metronidazole is effective against anaerobic infections due to 
sufficient negative redox potential from the presence of electron transport proteins. 
Once metronidazole enters the cytoplasm via passive diffusion, the electron acceptors 
have lower redox potential than metronidazole thus donating its electron to the drug. 
The drug is ‘activated’ to a nitroso free radical that is cytotoxic. The actual mechanism 
of action on DNA molecule is unknown but it has been speculated that the activated 
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metronidazole binds to DNA molecule, inhibiting DNA synthesis and causing DNA 
damage by oxidation that leads to DNA degradation and cell death (Reysset, 1996). 
 
Although there are no clinically reported metronidazole resistance cases, trophozoites 
managed to acquire metronidazole resistance in vitro. Upcroft’s group introduced 
metronidazole resistance to E. histolytica trophozoites after 177 days of selection 
under microaerophilic conditions (to stimulate actual conditions after tissue invasion) 
and subsequently the trophozoites were maintained in medium with 10 µM of 
metronidazole (Samarawickrema et al., 1997). Wassmann’s group were maintaining 
trophozoites in medium with 40 µM metronidazole (Wassmann et al., 1999). It is 
difficult to generate metronidazole resistance in E. histolytica trophozoites in vitro 
however experiments conducted showed that it is possible for the trophozoites to 
tolerate constant exposure to metronidazole dosages that are comparable to the 
recommended dosages currently used in treating amoebiasis.  
 
Investigation on metronidazole resistant E. histolytica showed that there was 
significant increase in superoxide dismutase (SOD) activity and peroxiredoxin 
meanwhile expression of flavin reductase and ferredoxin 1 decreased. SOD and 
peroxidase are responsible for oxygen scavenging. The metronidazole resistant 
mechanism may be explained in the following ways: SOD may be able to detoxify 
nitro radicals from metronidazole activation. Nitro radicals produced can be removed 
by SOD that forms hydrogen peroxide. The detoxification of hydrogen peroxide may 
be catalyzed by peroxiredoxin; flavin reductase may function as a nitroreductase, with 
the reduced flavin oxidized by metronidazole that leads to formation of nitro radical; 
microaerophilic conditions causes flavin reductase to reduce oxygen, thus leading to 
19 
 
formation of hydrogen peroxide (Wassmann et al., 1999). Clinical resistance of 
metronidazole were found in the anaerobic Giardia lamblia and Trichomonas 
vaginalis (Upcroft and Upcroft, 2001). Experts have warned against the use of short-
term and sub-lethal levels exposure of metronidazole for prophylaxis purposes to 
prevent induction of drug resistance (Upcroft and Upcroft, 2001).   
 
EhCK (XM_652388.1) is genetically homologous to hCKα2 (NM_001277.2), based 
on sequence comparison from E. histolytica Genome Project (Chang, 2012). hCKα2 is 
a vastly investigated gene due to its association with tumorigenesis and its major role 
in phosphatidylcholine biosynthesis (Gallego-Ortega et al., 2009, de Molina et al., 
2002). Many anti-CK drugs are currently being developed, by targeting the choline 
and ATP binding pocket of CKα (de la Cueva et al., 2013, Falcon et al., 2013, Hudson 
et al., 2013). Commercially available known CK inhibitors and compounds with 
structural similarities to choline/ATP tested in this study were: 2-amino-1-butanol, 
miltefosine, choline kinase α inhibitor (CK37), flavopiridol, H-89 dihydrochloride (H-
89) hydrate, hemicholinium-3 (HC-3), hexadecyltrimethylammonium bromide 
(HDTAB), and thiamine hydrochloride.  
  
HC-3 is the prototype for CK inhibitors since 1954 (Long and Schueler, 1954). HC-3 
administration has found to have off-target action on acetylcholinesterase and presents 
high toxicity to cells (Boobis et al., 1975). It is a well-known choline competitive 
inhibitor that is highly selective towards choline kinase however it has a downside by 
having high toxicity that stems from its structural similarities to choline (Zech et al., 
2016). To reduce its toxicity but preserve its specificity, the structure of HC-3 has been 
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modified but preserving the symmetrical bis-quaternary structure (Hernández-
Alcoceba et al., 1997). 
 
Improvisation of HC-3 was done on alternating hydrophobic spacer length between 
quaternary ammonium groups (Bhattacharyya et al., 1987), the linker moiety, steric 
hindrance, and the electron donating groups (Janardhan et al., 2006). Other than HC-
3 and its derivatives, many other structures such as bis-pyridiniums, bis-quinoliniums, 
and non-symmetric inhibitors have been explored to increase potency and reduce 
toxicity (Figure 1.7) (Arlauckas et al., 2016). Many different HC-3 derivates have been 
produced such as MN58b (Hernández-Alcoceba et al., 1999) and RSM-932A 
(Zimmerman et al., 2013, Lacal and Campos, 2014). RSM-932A, also known as TDC-
717 has recently completed its Phase Ⅰ clinical trial successfully (Lacal and Campos, 
2014). 
 
N - ( 3 ,5 - d i m e t h y l p h e ny l ) - 2 - [ [ 5 - ( 4 - e t h y l p h e n y l ) - 1 H - 1 , 2 , 4 - t r i a z o l - 3 - y l ] s u l f a n y l ]
acetamide, CK37 was discovered through in silico molecular modeling. It was found 
to inhibit recombinant CKα by targeting the choline binding site. CK37 inhibits 
endogeneous HeLa CK activity at 1 µM - 10 µM and caused a decrease in 
phosphocholine and its downstream metabolites (Clem et al., 2011). CK37 dose-
dependently suppressed 6 different tumor cell lines (IC50 between 5 µM- 10 µM in 48 
hours) and selectively exhibit tumor growth suppression in MDA-MB-231 mammary 
carcinoma cells (IC50 = 10 µM) compared to Human Mammary Epithelial Cells 





Figure 1.7  CK inhibitors and their structures. CK37 belongs to 
asymmetry  inhibitor that was developed via 




Flavopiridol (also known as Alvocidib), a flavonoid alkaloid, is a cyclin-dependent  
kinase inhibitor that acts on CDK9 and CDK 4/6 (Senderowicz, 1999). A combined 
treatment of SN-38 (metabolite of irinotecan) and flavopiridol reduced 
phosphocholine:choline concentration in HCT-116 by 67% (Darpolor et al., 2011). 
Flavopiridol was found to have clinical activity against chronic lymphotic leukemia 
(CLL), acute myeloid leukemia (AML), hepatocellular carcinoma, ovarian carcinoma, 
breast cancer, prostate cancer, and uterine leiomyoma (Wiernik, 2016). It is an ATP 
competitive inhibitor that promotes apoptosis by preventing cell cycle progression in 
G2-M or G1-S phase (Baguley and Kerr, 2002). Combination of flavopiridol and other 
drugs found success in treatment of AML, however its high toxicity, difficult 
prescription, and emerging of new single-drugs with less toxicity made it unable to 
advance into phase Ⅲ trial (Wiernik, 2016).  
 
A potent inhibitor of protein kinase A (PKA), H-89 also inhibits other kinases such as 
S6KⅠ, ROCKⅡ, KBα and MAPKAP-K1b (Lochner and Moolman, 2006). H-89 blocks 
PKA through competitive inhibition of ATP at the ATP site of PKA catalytic subunit 
(Hidaka et al., 1984). H-89 inhibits CK dose-dependently with an IC50 = 35 µM, with 
phosphatidylcholine concentration of HeLa cells decreased upon presence of 10 µM 
H-89 (Wieprecht et al., 1994, Gabellieri et al., 2009). Although H-89 could not inhibit 
PfCK (Choubey et al., 2007) and its binding mechanism on CK is still unknown, it 
was chosen for this study based on its ability to inhibit hCK.  
 
Better known as vitamin B1 hydrochloride, thiamine HCl is essential for aerobic 
metabolism, cell growth, transmission of nerve impulses and acetylcholine synthesis 
(Thomson et al., 1987, Brin, 1962). Thiamine HCl is phosphorylated by thiamine 
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pyrophosphokinase-1 (TPK1) to form active thiamine pyrophosphate which is a 
coenzyme for enzymatic activities in fatty acid, amino acid, and carbohydrate 
metabolism (Nosaka et al., 2001). Alteration to thiamine homeostasis was found to 
have significant correlation to the increase of cancer cell proliferation, with studies 
suggest that cancer cells utilize thiamine-dependent enzymes and pathways for 
proliferation and survival (Zastre et al., 2013, Liu et al., 2010). Thiamine HCl was 
chosen in this study as one of the inhibitors based on its structural similarities to 
choline substrate.  
 
HDTAB (also abbreviated as CTAB) is frequently used in plant DNA extraction. A 
cationic detergent, CTAB forms micelles, a structure similar to plasma membrane, 
which allows them to incorporate themselves into the membrane phospholipids and 
disrupt the membrane structure. The quaternary ammonium compound, HDTAB was 
selected as an inhibitor candidate in this study due to its structural similarities to 
miltefosine, an anti-proliferative and anti-leishmanial drug (Choubey et al., 2007). 
Quaternary ammonium derivatives have also been reported to exhibit antitumor 
activity (Giraud et al., 2002). HDTAB inhibits PfCK in a dose-dependent manner with 
60% of PfCK activity inhibited at 100 µM by competing with choline at its binding 
site (Choubey et al., 2007). In the case of tumorigenesis, HDTAB inhibits proliferation 
of prostate cancer cells besides being identified as a potential candidate in treatment 
of head and neck cancer (Ito et al., 2009, Wissing et al., 2013). HDTAB targets cancer 
cells by inhibition of ATP synthase, preventing mitochondrial membrane potential 




1.6 Gene silencing of E. histolytica 
The phenomenon of double stranded RNA in blocking mRNA was discovered by 
Andrew Fire and Craig Mello in 1998 and was dubbed as RNA interference (RNAi) 
(Fire et al., 1998). Since then, RNAi has come a long way to its current use in clinical 
trials of numerous diseases. RNAi is a catalytic pathway initiated by double stranded 
RNA (dsRNA). The triggering of this pathway may stem from the naturally occurring 
dsRNA in the cells, or by introducing dsRNA artificially using certain techniques. 
Although the mechanism of this pathway differs with organisms, the fundamental 
principles of RNAi generally starts from introduction of dsRNA. A protein named 
Dicer, then processes dsRNA into small interfering RNA (siRNA). A single guide 
strand siRNA was recognized and incorporated into RNA-induced silencing complex 
(RISC). This siRNA guides RISC complex to complementary mRNA target where the 
target mRNA is sliced and transcription is halted (Ghildiyal and Zamore, 2009). 
Ultimately, RNAi causes downregulation of the target gene by degrading its mRNA.  
 
Prior to Andrew Fire and Craig Mello discovery that dsRNA induces highly specific 
and potent downregulation in C. elegans, antisense RNA strand has been used in 
regulating gene expression (Fire et al., 1998). Antisense RNA was able to regulate 
gene expression although the downregulation was not as potent as using dsRNA 
(Nishikura and Murray, 1987). Scientists wanted to use antisense RNA as a therapeutic 
agent but due to its low potency at low concentrations, there was a raised concern on 
increasing RNA concentrations as it may lead to cytotoxicity issues (Farrell, 1993). 
Now dsRNAs, together with other types of siRNAs are used in clinical trials for 
diseases such as eye diseases, hypercholesterolemia, haemophilia, viruses, and 
multiple types of cancer (Bobbin and Rossi, 2016).  
